Julien Rohmer

Julien Rohmer

Auto-generated profile, based on publicly available information

Julien Rohmer

Médecine interne, hôpital Cochin, rue du Faubourg-Saint-Jacques, Paris

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
JRJulien Rohmer
Julien Rohmer
ACAmélie Couteau‐Chardon
Amélie Couteau‐Chardon
JTJulie Trichereau
Julie Trichereau
KPKewin Panel
Kewin Panel
CGCyrielle Gesquiere
Cyrielle Gesquiere
CCCereo And Gbmhm Collaborators
Cereo And Gbmhm Collaborators

1 August 2023 in Journal of Autoimmunity
Verified
Journal Article
Closed access
JRJulien Rohmer
Julien Rohmer
YNYann Nguyen
Yann Nguyen
LTLudovic Trefond
Ludovic Trefond
CAChristian Agard
Christian Agard
JAJean Sebastien Allain
Jean Sebastien Allain
FVFrederic Vandergheynst
Frederic Vandergheynst

1 October 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
JTJuliette Tennenbaum
Juliette Tennenbaum
MGMatthieu Groh
Matthieu Groh
LVLaura Venditti
Laura Venditti
FCFrance Campos-Gazeau
France Campos-Gazeau
ECEmilie Chalayer
Emilie Chalayer
JRJulien Rohmer
Julien Rohmer
Background and Purpose: Ischemic stroke has been reported in various conditions associated with eosinophilia. FIP1L1-PDGFRA fusion ([Fip1-like 1-platelet-derived growth factor receptor alpha]; F/P ) leads to the proliferation of the eosinophilic lineage and thus to a clonal hypereosinophilic syndrome that is highly responsive to imatinib. Methods: We previously reported on a nationwide retrospective study of 151 patients with F/P -associated clonal hypereosinophilic syndrome. Patients from this cohort with a clinical history of ischemic stroke (as well as 2 additional cases) were further analyzed to better define their clinical picture and outcomes. Results: Sixteen male patients (median age, 51 [43–59] years) with low-to-intermediate cardiovascular risk were included. Median National Institutes of Health Stroke Scale was 4 (range, 1–6). Most cerebral imaging disclosed multiple bilateral infarctions of watershed distribution (69%). Despite frequent cardiac involvement (50%), cardiac thrombus was evidenced in a single patient and, according to the TOAST classification (Trial of ORG 10172 in Acute Stroke Treatment), 62.5% of strokes were presumably of undetermined etiology. Among the 15 patients treated with imatinib, and after a median follow-up of 4.5 years, stroke recurred in only 3 patients (consisting of either cardio embolic or hemorrhagic events, unrelated to the first episode). Conclusions: F/P + clonal hypereosinophilic syndrome is a diagnosis to consider in patients with unexplained ischemic stroke and hypereosinophilia (especially in the setting of multiple cortical borderzone distribution) and warrants prompt initiation of imatinib.

1 December 2014 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
FDF.X. Danlos
F.X. Danlos
FDF. Daoued
F. Daoued
JRJ. Rohmer
J. Rohmer
GCG. Cluzel
G. Cluzel
HFH. François
H. François
XMXavier Mariette
Xavier Mariette

1 December 2020 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
JTJ. Tennenbaum
J. Tennenbaum
MGM. Groh
M. Groh
LVL. Venditti
L. Venditti
FGF. Campos Gazeau
F. Campos Gazeau
ECEmilie Chalayer
Emilie Chalayer
JRJ. Rohmer
J. Rohmer

27 November 2023 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
PCP. Cioni
P. Cioni
YNYann Nguyen
Yann Nguyen
JRJ. Rohmer
J. Rohmer
HDH. Dupuy
H. Dupuy
XPX. Puéchal
X. Puéchal
BTB. Terrier
B. Terrier